JP7829491B2 - ６－チオ－ｄＧ、チェックポイント阻害剤および放射線療法を使用するがんの逐次処置 - Google Patents

６－チオ－ｄＧ、チェックポイント阻害剤および放射線療法を使用するがんの逐次処置

Info

Publication number
JP7829491B2
JP7829491B2 JP2022554769A JP2022554769A JP7829491B2 JP 7829491 B2 JP7829491 B2 JP 7829491B2 JP 2022554769 A JP2022554769 A JP 2022554769A JP 2022554769 A JP2022554769 A JP 2022554769A JP 7829491 B2 JP7829491 B2 JP 7829491B2
Authority
JP
Japan
Prior art keywords
thio
cancer
cells
tumor
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022554769A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517671A (ja
JP2023517671A5 (enExample
Inventor
ジェリー シャイ
ヤン－シン フー
イルゲン メンデル
アンリ ジャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2023517671A publication Critical patent/JP2023517671A/ja
Publication of JP2023517671A5 publication Critical patent/JP2023517671A5/ja
Application granted granted Critical
Publication of JP7829491B2 publication Critical patent/JP7829491B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
JP2022554769A 2020-03-13 2021-03-12 ６－チオ－ｄＧ、チェックポイント阻害剤および放射線療法を使用するがんの逐次処置 Active JP7829491B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062989041P 2020-03-13 2020-03-13
US62/989,041 2020-03-13
PCT/US2021/022090 WO2021183873A1 (en) 2020-03-13 2021-03-12 Sequential treatment of cancers using 6-thio-dg, checkpoint inhibitors and radiation therapy

Publications (3)

Publication Number Publication Date
JP2023517671A JP2023517671A (ja) 2023-04-26
JP2023517671A5 JP2023517671A5 (enExample) 2024-03-05
JP7829491B2 true JP7829491B2 (ja) 2026-03-13

Family

ID=77671975

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022554769A Active JP7829491B2 (ja) 2020-03-13 2021-03-12 ６－チオ－ｄＧ、チェックポイント阻害剤および放射線療法を使用するがんの逐次処置

Country Status (16)

Country Link
US (2) US12097213B2 (enExample)
EP (1) EP4117667B1 (enExample)
JP (1) JP7829491B2 (enExample)
KR (1) KR20220154134A (enExample)
CN (1) CN115397428A (enExample)
BR (1) BR112022018238A2 (enExample)
CA (1) CA3170930A1 (enExample)
DK (1) DK4117667T3 (enExample)
ES (1) ES3014683T3 (enExample)
FI (1) FI4117667T3 (enExample)
HU (1) HUE070513T2 (enExample)
IL (1) IL296403A (enExample)
MX (1) MX2022011331A (enExample)
PL (1) PL4117667T3 (enExample)
PT (1) PT4117667T (enExample)
WO (1) WO2021183873A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210023107A1 (en) 2018-03-22 2021-01-28 The Board Of Regents Of The University Of Texas System USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS
WO2025090539A1 (en) * 2023-10-22 2025-05-01 Regeneron Pharmaceuticals, Inc. Treatment of non-small cell lung cancer with 6-thio-dg and cemiplimab

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017165675A1 (en) 2016-03-24 2017-09-28 The Board Of Regents Of The University Of Texas System Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds
WO2017205756A1 (en) 2016-05-27 2017-11-30 The Board Of Regents Of The University Of Texas System 6-thio-2'-deoxyguanosine (6-thio-dg) results in telomerase dependent telomere dysfunction and cell death in therapy-resistant cancer cells
WO2018187227A1 (en) 2017-04-03 2018-10-11 Concologie, Inc. Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2630255B1 (en) * 2010-10-22 2014-09-10 Roche Diagnostics GmbH A conjugate between a thiophilic solid phase and an oligonucleotide comprising a thiooxonucleotide
NZ713498A (en) 2013-04-08 2017-07-28 Univ Texas Mercaptopurine ribonucleoside analogues for altering telomerase mediated telomere
CA2991628C (en) * 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
WO2018049474A1 (en) 2016-09-16 2018-03-22 Bionomics Limited Antibody and checkpoint inhibitor combination therapy
MA47604A (fr) 2017-02-21 2020-01-01 Regeneron Pharma Anticorps anti-pd-1 pour le traitement du cancer du poumon
EP3746119A4 (en) * 2018-02-01 2021-11-10 Merck Sharp & Dohme Corp. METHOD OF TREATMENT FOR CANCER OR INFECTION USING A COMBINATION OF ANTI-PD-1 ANTIBODY, ANTI-LAG3 ANTIBODY, AND ANTI-TIGITE ANTIBODY
US20210113602A1 (en) 2018-02-28 2021-04-22 The Board Of Regents Of The University Of Texas System USE OF 6-THIO-2'-DEOXYGUANOSINE (6-THIO-dG) TO TREAT MELANOMA
US20210023107A1 (en) 2018-03-22 2021-01-28 The Board Of Regents Of The University Of Texas System USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017165675A1 (en) 2016-03-24 2017-09-28 The Board Of Regents Of The University Of Texas System Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds
WO2017205756A1 (en) 2016-05-27 2017-11-30 The Board Of Regents Of The University Of Texas System 6-thio-2'-deoxyguanosine (6-thio-dg) results in telomerase dependent telomere dysfunction and cell death in therapy-resistant cancer cells
WO2018187227A1 (en) 2017-04-03 2018-10-11 Concologie, Inc. Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer Cell，2020年09月14日，38，pp.400-411, e1-e6，DOI: 10.1016/j.ccell.2020.05.020
Clinical Cancer Research，2018年，24(19)，pp.4629-4630，DOI: 10.1158/1078-0432.CCR-18-0989

Also Published As

Publication number Publication date
WO2021183873A1 (en) 2021-09-16
PL4117667T3 (pl) 2025-04-07
IL296403A (en) 2022-11-01
US12097213B2 (en) 2024-09-24
US20210290652A1 (en) 2021-09-23
EP4117667A4 (en) 2023-11-15
CA3170930A1 (en) 2021-09-16
JP2023517671A (ja) 2023-04-26
DK4117667T3 (da) 2025-02-10
FI4117667T3 (fi) 2025-02-10
EP4117667A1 (en) 2023-01-18
AU2021233023B2 (en) 2026-04-16
PT4117667T (pt) 2025-02-06
ES3014683T3 (en) 2025-04-24
EP4117667B1 (en) 2024-12-18
AU2021233023A1 (en) 2022-11-03
HUE070513T2 (hu) 2025-06-28
MX2022011331A (es) 2022-10-27
BR112022018238A2 (pt) 2022-10-25
CN115397428A (zh) 2022-11-25
KR20220154134A (ko) 2022-11-21
US20240424013A1 (en) 2024-12-26

Similar Documents

Publication Publication Date Title
US20190077856A1 (en) Method of treating diseases using kinase modulators
Luo et al. Necroptosis-dependent immunogenicity of cisplatin: implications for enhancing the radiation-induced abscopal effect
US20170326205A1 (en) Methods and compositions for treatment of metastatic and refractory cancers and tumors
JP2020535173A (ja) Ｈｓｐ９０阻害剤に関係する治療方法
CN114729358A (zh) 涉及miRNA-193a的新疗法
KR20230059792A (ko) 암 치료를 위한 조합
US20240424013A1 (en) SEQUENTIAL TREATMENT OF CANCERS USING 6-THIO-dG, CHECKPOINT INHIBITORS AND RADIATION THERAPY
US20240009223A1 (en) 6-thio-2'-deoxyguanosine (6-thio-dg) results in telomerase dependent telomere dysfunction and cell death in various models of therapy-resistant cancer cells
CN111182917A (zh) 用于治疗癌症的免疫原性组合物
Franzese et al. Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors
US20200268864A1 (en) Cancer vaccine compositions and methods for using same to treat cancer
JP2022523423A (ja) ２’３’－環状ジヌクレオチドおよびそのプロドラッグ
Heimberger et al. Small molecular inhibitors of p-STAT3: novel agents for treatment of primary and metastatic CNS cancers
JP2022523571A (ja) ３’３’－環状ジヌクレオチドおよびそのプロドラッグ
US20240141436A1 (en) Compounds, Compositions and Methods of Treatment Thereof
RU2833475C1 (ru) ПОСЛЕДОВАТЕЛЬНОЕ ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ 6-ТИО-dG, ИНГИБИТОРОВ КОНТРОЛЬНЫХ ТОЧЕК И ЛУЧЕВОЙ ТЕРАПИИ
AU2021233023B9 (en) Sequential treatment of cancers using 6-thio-dg, checkpoint inhibitors and radiation therapy
HK40084657A (en) Sequential treatment of cancers using 6-thio-dg and checkpoint inhibitors
HK40084657B (en) Sequential treatment of cancers using 6-thio-dg and checkpoint inhibitors
Link Cancer therapy
CA3025522C (en) 6-thio-2'-deoxyguanosine (6-thio-dg) results in telomerase dependent telomere dysfunction and cell death in various models of therapy-resistant cancer cells
EP4583888A1 (en) Modified t-cells for use in the treatment of bladder cancer
JP2024503513A (ja) がんを処置するための併用療法スケジュール
IL301105A (en) Mdm2 inhibitors for use in the treatment or prevention of hematologic neoplasm relapse after hematopoietic cell transplantation
Aquino Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220930

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221227

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251119

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260303

R150 Certificate of patent or registration of utility model

Ref document number: 7829491

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150